Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
455120
Reference Type
Journal Article
Subtype
Review
Title
Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome
Author(s)
Bosma, KJ; Lewis, JF
Year
2007
Is Peer Reviewed?
Yes
Journal
Expert Opinion on Emerging Drugs
ISSN:
1472-8214
Volume
12
Issue
3
Page Numbers
461-477
Language
English
PMID
17874973
DOI
10.1517/14728214.12.3.461
Abstract
Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a life-threatening form of respiratory failure that affects a heterogeneous population of critically ill patients. Although overall mortality appears to be decreasing in recent years due to improvements in supportive care, there are presently no proven, effective pharmacological therapies to treat ARDS and prevent its associated complications. The most common cause of death in ARDS is not hypoxemia or pulmonary failure, but rather multiple organ dysfunction syndrome (MODS), suggesting that improving survival in patients with ARDS may be linked to decreasing the incidence or severity of MODS. The key to developing novel treatments depends, in part, on identifying and understanding the mechanisms by which ARDS leads to MODS, although the heterogeneity and complexity of this disorder certainly poses a challenge to investigators. Novel therapies in development for treatment of ALI/ARDS include exogenous surfactant, therapies aimed at modulating neutrophil activity, such as prostaglandin and complement inhibitors, and treatments targeting earlier resolution of ARDS, such as beta-agonists and granulocyte macrophage colony-stimulating factor. From a clinical perspective, identifying subpopulations of patients most likely to benefit from a particular therapy and recognising the appropriate stage of illness in which to initiate treatment could potentially lead to better outcomes in the short term.
Keywords
acute lung injury; acute respiratory distress syndrome; clinical trial; drug therapy; inflammatory mediator; surfactant; colony-stimulating factor; randomized controlled-trial; partial liquid; ventilation; critically-ill patients; inhaled nitric-oxide; phase-ii; trial; mechanical ventilation; tidal volume; double-blind; organ; dysfunction
Tags
PFAS
•
Additional PFAS (formerly XAgency)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity